ORIGINAL ARTICLE



Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis

Christian Trapp¹ · Daniel M. Aebersold² · Claus Belka^{1,3} · Jozefina Casuscelli⁴ · Louise Emmett^{5,6} · Chukwuka Eze¹ · Stefano Fanti⁷ · Andrea Farolfi⁷ · Wolfgang Fendler⁸ · Anca-Ligia Grosu^{9,10} · Matthias Guckenberger¹¹ · George Hruby¹² · Simon Kirste⁹ · Stefan A. Koerber^{13,14} · Stephanie Kroeze¹¹ · Jan C. Peeken^{3,15} · Paul Rogowski¹ · Sophia Scharl¹⁶ · Mohamed Shelan² · Simon K. B. Spohn^{9,10,17} · Iosif Strouthos¹⁸ · Lena Unterrainer^{19,20} · Marco Vogel^{3,15} · Thomas Wiegel¹⁶ · Constantinos Zamboglou^{9,10,18} · Nina-Sophie Schmidt-Hegemann¹

Received: 13 March 2024 / Accepted: 10 June 2024 / Published online: 28 June 2024 © The Author(s) 2024

Abstract

Purpose Despite growing evidence for bilateral pelvic radiotherapy (whole pelvis RT, WPRT) there is almost no data on unilateral RT (hemi pelvis RT, HPRT) in patients with nodal recurrent prostate cancer after prostatectomy. Nevertheless, in clinical practice HPRT is sometimes used with the intention to reduce side effects compared to WPRT. Prostate-specific membrane antigen positron emission tomography / computed tomography (PSMA-PET/CT) is currently the best imaging modality in this clinical situation. This analysis compares PSMA-PET/CT based WPRT and HPRT.

Methods A propensity score matching was performed in a multi-institutional retrospective dataset of 273 patients treated with pelvic RT due to nodal recurrence (214 WPRT, 59 HPRT). In total, 102 patients (51 in each group) were included in the final analysis. Biochemical recurrence-free survival (BRFS) defined as prostate specific antigen (PSA) < post-RT nadir+0.2ng/ml, metastasis-free survival (MFS) and nodal recurrence-free survival (NRFS) were calculated using the Kaplan-Meier method and compared using the log rank test.

Results Median follow-up was 29 months. After propensity matching, both groups were mostly well balanced. However, in the WPRT group there were still significantly more patients with additional local recurrences and biochemical persistence after prostatectomy. There were no significant differences between both groups in BRFS (p=.97), MFS (p=.43) and NRFS (p=.43). After two years, BRFS, MFS and NRFS were 61%, 86% and 88% in the WPRT group and 57%, 90% and 82% in the HPRT group, respectively. Application of a boost to lymph node metastases, a higher RT dose to the lymphatic pathways (> 50 Gy EQD2_{$\alpha/\beta=1.5 Gy}) and concomitant androgen deprivation therapy (ADT) were significantly associated with longer BRFS in uni- and multivariate analysis.</sub>$

Conclusions Overall, this analysis presents the outcome of HPRT in nodal recurrent prostate cancer patients and shows that it can result in a similar oncologic outcome compared to WPRT. Nevertheless, patients in the WPRT may have been at a higher risk for progression due to some persistent imbalances between the groups. Therefore, further research should prospectively evaluate which subgroups of patients are suitable for HPRT and if HPRT leads to a clinically significant reduction in toxicity.

Keywords Prostate cancer · Nodal recurrence · PSMA PET/CT · Radiotherapy · Hemi pelvis · Whole pelvis

Extended author information available on the last page of the article

Background

After radical prostatectomy, approximately one third of prostate cancer (PC) patients have a biochemical persistence or develop a biochemical recurrence [1, 2]. Nowadays, in this situation many patients are staged with prostate-specific membrane antigen positron emission tomography / computed tomography (PSMA-PET/CT), which often reveals lymph node metastases (LNM) [3]. The optimal therapeutic strategies are still subject to ongoing discussion, reaching from androgen deprivation therapy (ADT), salvage lymph node dissection (sLND) to radiotherapeutic approaches. The latter include stereotactic body radiotherapy (SBRT) or irradiation of the pelvic lymphatic pathways (whole pelvis RT, WPRT), possibly with a simultaneous integrated boost (SIB) to LNM. Regarding SBRT, there is evolving evidence from retrospective trials [4, 5] and prospective phase I and II trials in patients with oligometastatic prostate cancer (PC) which included many patients with LNM [6–10]. Regarding WPRT with SIB to LNM, there are some retrospective outcome analyses [11–14] and a prospective phase II trial reporting the outcome of WPRT+6 months ADT [15]. Furthermore, a retrospective multi-institutional comparison between WPRT and SBRT showed a better metastasis-free survival (MFS) in patients treated with WPRT [16]. Randomized data can be awaited from the "Oligopelvis 2 GETUG P12" trial, which randomizes patients between intermittent ADT+WPRT vs. intermittent ADT alone (NCT03630666) and the "Peace V - Storm" trial [17], which randomizes patients between 6 months ADT + metastasis directed therapy (MDT) (sLND or SBRT) vs. 6 months ADT + MDT + WPRT. Nevertheless, in the absence of definitive prospective evidence some institutions currently treat patients also with individualized concepts, e.g. an "involved field RT" [18, 19] or an unilateral RT of the pelvic lymphatic pathways on the side of the LNM (hemi pelvis RT, HPRT) with the intent to reduce the locoregional failure rate while keeping toxicity low. In this retrospective analysis we compare the results of PSMA-PET/CT guided HPRT with WPRT based on a large multi-institutional dataset allowing propensity score matching.

Methods

Patient population

This analysis is based on a retrospective dataset of eleven centers in five countries (6 German centers, 2 Swiss centers, 1 Australian center, 1 Cypriot center, 1 Italian center). The dataset includes 1222 PC patients who received PSMA-PET/CT guided salvage RT due to PSA recurrence or PSA persistence after prostatectomy. Details regarding PET/CT protocols, RT protocols and follow up concepts can be found in the supplements of an earlier publication [20]. In 407 of these 1222 patients PSMA-PET/CT detected LNM. After cleaning up the dataset by removing patients with insufficient or incomplete follow up and patients who did not receive a RT of the lymphatic pathways (e.g. patients who were treated by SBRT), the dataset contained 273 cases. 214 of these patients received WPRT while 59 patients received HPRT.

In a next step, propensity score matching was performed using IBM-SPSS[®] version 29. Use of ADT (yes or no), prostate specific antigen (PSA) value before PSMA-PET/CT (≤ 0.2 ng/ml, 0.21–0.5 ng/ml, 0.51–1.0 ng/ml or > 1.0 ng/ ml), age and ISUP-Score (≤ 3 or ≥ 4) were used as matching variables. A matching tolerance of 0.01 was chosen.

Propensity score matching resulted in a final dataset consisting of 102 patients (51 in each group). Regarding patients' characteristics the groups of the final dataset still significantly differed in the proportion of patients with biochemical persistence after prostatectomy (43% in the WPRT vs. 16% in the HPRT group) and the presence of an additional local recurrence in PSMA-PET/CT (33% vs. 6%). Nevertheless, incorporating those parameters into the matching algorithm resulted in a very limited dataset with no precise matches so that we decided to proceed with the 102 patient - dataset.

Ethics

Local ethics committees of participating centers approved this study (University of Freiburg, Freiburg, Germany; University of Munich, Munich, Germany; Technical University of Munich, Munich, Germany; University of Bologna, Bologna, Italy; University of Ulm, Ulm, Germany; Ethics Committee Zuerich, Zuerich, Switzerland; University of New South Wales, Sydney, Australia; University of Heidelberg, Heidelberg, Germany; Cyprus National Bioethics Committee, Nicosia, Cyprus; Cantonal Ethics Commission Bern, Bern, Switzerland). Written informed consent was waived due to the retrospective character of the study in accordance with all respective review boards.

PET/CT

PET/CT acquisition and interpretation was performed in accordance with the local practice of all participating centers as shown in [20]. ⁶⁸Ga-PSMA or ¹⁸F-PSMA were used.

Statistics

Primary endpoint was biochemical recurrence-free survival (BRFS). Biochemical recurrence was defined as a rise of 0.2 ng/ml above the post-RT nadir. Secondary endpoints were MFS and nodal recurrence-free survival (NRFS). Metastases were defined as hematogenous metastases or supradiaphragmatic LNM. Nodal recurrence was defined as recurrence in a pelvic or paraaortic lymph node. Survival analyses were based on time from last day of RT to bio-chemical progression / diagnosis of a new metastasis, death or to the date of the last follow-up. Statistical analyses were conducted using IBM-SPSS® version 29. Survival analyses were calculated using the Kaplan-Meier method and compared using the log-rank test. Predictive factors for BRFS were evaluated by uni- and multivariate Cox regression analyses in the whole dataset (102 patients).

Results

Patients' and treatment characteristics

After propensity score matching, the final dataset consisted of 102 patients (51 per group). Patients' characteristics were mostly similar in both groups (see Table 1). Regarding T stage, N stage, R status and ISUP score there were no significant differences. The PSA value before PET/CT was similar in both groups, too. The only significant differences relate to the percentages of patients with PSA persistence after prostatectomy (43% in the WPRT group vs. 16% in the HPRT group) and with the finding of an additional local recurrence in the PSMA-PET/CT (33% in the WPRT vs. 6% in the HPRT group). Treatment characteristics were also mostly well balanced between both groups (see Table 1). The percentage of patients with additional RT of the prostate bed and the dose to the lymphatic pathways were similar as well as the percentage of patients with additional ADT and the duration of the ADT treatment. Regarding treatment characteristics, only the dose of the LNM boost differed significantly (59% vs. 0% received > 60 Gy equivalent dose in 2 Gy fractions (EQD2)_{$\alpha/B=1.5$ Gy} in the WPRT and HPRT group, respectively). The median follow up was longer in the WPRT group (40 vs. 24 months).

Biochemical recurrence-free survival

We did not observe significant differences in BRFS (p = .97). BRFS after two years was 61% in the WPRT group and 57% in the HPRT group. Median BRFS was 36 months in WPRT patients and was not reached in HPRT patients (see Fig. 1).

Metastasis-free survival and nodal recurrence-free survival

MFS and NRFS were also similar in both groups (p = .43 for MFS, p = .23 for NRFS). After two years, MFS was 86% in the WPRT group vs. 90% in the HPRT group and NRFS was 88% in the WPRT group vs. 82% in the HPRT group, respectively. Regarding MFS and NRFS, medians were not reached in both groups (see Figs. 2 and 3).

Univariate and multivariate analysis

Univariate analysis of the whole dataset (WPRT and HPRT) reveals that a RT dose to the lymphatic pathways of EQD2_{$\alpha/\beta=1.5 \text{ Gy}$} > 50 Gy, the application of a LNM boost, additional RT of the prostate bed and concomitant ADT were significant predictors of BRFS. In the multivariate Cox regression analysis of these factors all but additional RT to the prostate bed could be confirmed as significant predictors (see Table 2).

Discussion

In the present analysis we found similar oncologic results of WPRT and HPRT in PSMA-PET/CT- positive nodal recurrences after prostatectomy. There were no significant differences in BRFS, MFS and NRFS. After two years, BRFS, MFS and NRFS were 61%, 86%, 88% after WPRT and 57%, 90%, 82% after HPRT, respectively.

This analysis stands in line with previous retrospective datasets evaluating different radiotherapeutic approaches for nodal recurrent PC. Retrospective mono- and multiinstitutional series analysing the outcome of SBRT of LNM reported progression-free survival (PFS) rates of approximately 30% after 2 years and distant PFS rates of approximately 40-50% after 2 years [4, 21-23]. In these series approximately 40 to 50% of patients received ADT and patients were mostly staged with choline PET/CT. Correspondingly, the prospective phase II trials ORIOLE and STOMP evaluating MDT in oligometastastic PC included also patients with LNM and reported PFS rates of 60% after 2 years [6, 7]. Patients in these trials did not receive ADT and were staged by conventional imaging or choline PET/CT. When looking at WPRT, there are also some retrospective studies reporting the outcome. Tamihardja et al. found a biochemical progression rate of 50.1% after 5 years. 71% of patients were staged by PSMA-PET/CT and 60% received ADT. PSMA-PET/CT was associated with a significantly better outcome compared with choline PET/CT [14]. Rogowski et al. found a BRFS of 72% after 2 years in a patient cohort completely staged by PSMA-PET/CT. 83%

		WPRT	HPRT	
Age	[years]	71 (53–78)	71 (51–87)	$p = 0.95^{-1}$
pT S	Stage			$p = 0.34^{2}$
-	pT2	21 (41%)	27 (53%)	
-	pT3a	9 (18%)	11 (22%)	
-	pT3b	16 (31%)	10 (20%)	
-	pT4	1 (2%)	0	
-	no data available	4 (8%)	3 (6%)	
pN	Stage			$p = 0.28^{3}$
-	pN0	34 (67%)	37 (73%)	
-	pN1	11 (22%)	6 (12%)	
-	no data available	6 (12%)	8 (16%)	
R S	tatus			$p = 0.88^{3}$
-	R0	27 (53%)	37 (73%)	
-	R1	15 (29%)	8 (16%)	
-	no data available	9 (18%)	6 (12%)	
ISU	P Score			$p = 0.76^{2}$
-	1 or 2	15 (29%)	17 (33%)	1
-	3	11 (22%)	14 (28%)	
-	4	15 (29%)	11 (22%)	
-	5	10 (20%)	9 (18%)	
PSA	Persistence after RPE	~ /		$p = 0.00^3$
-	persistence	22 (43%)	8 (16%)	I ·····
-	recurrence	28 (55%)	41 (80%)	
-	no data available	1 (2%)	2 (4%)	
PSA	before PET/CT [ng / m]]		- ()	$n = 0.84^{2}$
-	<02	1 (2%)	1 (2%)	p otor
_	0.21-0.5	11 (22%)	12 (24%)	
_	0.51 - 1.0	13 (26%)	9 (18%)	
_	>10	26 (51%)	29 (57%)	
Loc	al Recurrence in PET/CT	_ (())		$n = 0.00^3$
-		34 (67%)	48 (94%)	<i>p</i> = 0.00
_	ves	17 (33%)	3 (6%)	
RT	of Prostate Bed	17 (0070)	3 (070)	$n = 0.29^{3}$
-	Ves	40 (78%)	40 (85%)	p = 0.25
_	no	11 (22%)	7 (15%)	
Boo	st of LNM	11 (2270)	, (10,0)	$n = 0.76^{3}$
-	Ves	46 (90%)	44 (86%)	<i>p</i> = 0.70
_	no.	5 (10%)	7 (14%)	
RT	Dose to Lymphatic Pathways [Gy]	5 (10/0)	, (11,0)	
				$n = 0.59^{3}$
_	FOD2 = 50 Gv	42 (82%)	44 (86%)	p = 0.55
	$EQD2_{\alpha/\beta=1.5 \text{ Gy}} \leq 50 \text{ Gy}$	7(14%)	7 (14%)	
-	$EQD2_{\alpha/\beta=1.5 \text{ Gy}} > 50 \text{ Gy}$	2(4%)	0	
- PT	Dose to LNM [Gy]	2 (470)	0	$n = 0$ 00^2
KI .	EOD2 < 50 Cm	1 (29/)	0	p = 0 .00
-	$EQD2_{\alpha/\beta=1.5 \text{ Gy}} \leq 50 \text{ Gy}$	1(270)	0	
-	$EQD2_{\alpha/\beta=1.5 \text{ Gy}} 50.1-60 \text{ Gy}$	12(24%)	44 (80%)	
-	$EQD2_{\alpha/\beta=1.5 \text{ Gy}} > 60 \text{ Gy}$	30 (39%)	0	
-	no data available	ð (10%)	/ (14%)	1.003
AD	i during KI	25 ((00/))	26 (710/)	$p = 1.00^{-5}$
-	yes	33 (09%) 16 (210/)	50 (/1%) 15 (200/)	
- P	no	10 (31%)	15 (29%)	0.00 2
Dur	ation of AD1	4 (00/)	2 (10/2	$p = 0.38^{-2}$
-	≤ 6 months	4 (8%)	2 (4%)	
-	> 6 and ≤ 12 months	5 (10%)	8 (16%)	

Table 1 (continued)

		WPRT	HPRT	
-	> 12 and \leq 24 months	5 (10%)	2 (4%)	
-	>24 months	1 (2%)	3 (6%)	
-	no data available	36 (71%)	36 (71%)	
Follow Up [months]		40 (14–84)	28 (12–64)	$p = 0.00^{1}$

 1 = t-test, 2 = chi square test, 3 = Fisher's exact test



Fig. 1 Biochemical recurrence-free survival (BRFS) in patients receiving whole pelvis RT (solid line) and hemi pelvis RT (broken line)

of patients received concomitant ADT [13]. The prospective OLIGOPELVIS GETUG P07 trial evaluated WPRT with SIB to LNM and 6 months of ADT and reported a BRFS of 58% after 2 years. However, all patients were staged by choline PET/CT [13]. Furthermore, there is a large retrospective multicenter analysis comparing SBRT and WPRT favoring WPRT with a MFS after 3 years of 68% (SBRT) and 77% (WPRT), respectively [16]. Patients were staged mostly by choline PET/CT and 23% (SBRT) vs. 60% (WPRT) of patients received ADT. Soldatov et al. performed a retrospective analysis evaluating PSMA-PET/CT-guided MDT including also patients with LNM recurrences and reported a biochemical progression in 43% of patients after 18 months [18]. Remarkably, in this series LNM were treated with an involved site approach (an external iliac LNM on the left side resulted in RT of the left-sided external iliac lymphatics). There is no clear information about concomitant ADT, but 24% of patients had ADT at time of PSMA-PET/CT.

All in all, compared to other publications we observed a comparably favorable oncologic outcome, probably due to PSMA-PET/CT staging and the large proportion of patients with concomitant ADT.

In our analysis, significant predictive factors in multivariate analysis were concomitant ADT, the application of a LNM boost and a dose to the pelvic lymphatics of > 50 Gy EQD2_{$\alpha/\beta=1.5$ Gy}. Concomitant ADT is a known predictive factor also described by other groups [13, 14]. Regarding the dose to the pelvic lymphatics there is insufficient data. The current NRG Oncology Group recommendations recommend 45–50.4 Gy [24]. Recent prospective trials including RT of the pelvic lymphatics used an EQD2_{$\alpha/\beta=1.5$ Gy} of 42.4 Gy [25, 26], 46.0 Gy [27], 47.5 Gy [28] or 50 Gy [29]. This work indicates that choosing 50.4 Gy should be considered – at least in the setting of nodal recurrent patients - and that the optimal dose still needs to be found in the future. To our knowledge there is no data on the influence of a LNM boost on oncologic outcome, although this is often



Fig. 2 Metastasis-free survival (MFS) in patients receiving whole pelvis RT (solid line) and hemi pelvis RT (broken line)



Fig. 3 Nodal recurrence-free survival (NRFS) in patients receiving whole pelvis RT (solid line) and hemi pelvis RT (broken line)

Table 2 Significant predictors of BRFS in the whole dataset (n = 102)

Partient CharacteristicsMedian B&PS [month]H24 (0.8% C.D)p-valuep-valuepT Stage1.24 (0.9-2.21)0.4759.794000pT3121.24 (0.9-2.21)0.4751.24 (0.9-2.21)0.475pT3-pT447221.01 (0.47-2.17)0.9851.01 (0.47-2.17)0.9851.01 (0.47-2.17)0.985pN0172271.01 (0.47-2.17)0.9851.01 (0.47-2.17)0.101 (0.17-17)0.101 (0.17-17)0.				Univariate Analysis		Multivariate Analysis	
pT Sage 1.24 (0.69-2.21) 0.475 pT3 - pT4 47 27 pN Suge 10 10.047-2.17) 0.985 pN Suge 10 0.047-2.17) 0.985 pN Suge 10 0.047-2.17) 0.985 pN I 7 2 pN I 7 2 R Status 0.070 (0.34-1.43) 0.327 R Status 0.30 0.37 R Status 0.10 (0.33-1.52) 0.380 StP Score 0.17 (0.33-1.52) 0.380 1-3 30 30 PSA recursce 10 0.10 (0.50-1.95) 0.828 PSA recursce 10 37 PSA recursce 12 127 (0.72-2.5) 0.412 Status 12 127 (0.72-2.5) 0.412 14 Status 12 12 12 12 Ing/m1 50 37 12 12 12 Ing/m1 50 37 12 14 14 12 Ing/m1 50 37 12 14<	Patient Characteristics	n	Median BRFS [months]	HR (95% CI)	<i>p</i> -value	HR (95% CI)	p-value
p12913913914914p13-p144727pN Ntage1116pN0172R Status0.70 (0.34-1.43)0.327R Status0.70 (0.34-1.43)0.327R Status0.70 (0.33-1.52)0.380R Status0.71 (0.33-1.52)0.380StUP Score19301-3301PSA Persistence NS PSA Recurrence1937PSA persistence301PSA persistence1037PSA tecurrence6337PSA tecurrence121.70 (0.52-1.52)0.412PSA tecurrence1336Statistical recurrence1236Statistical recurrence1336Statistical recurrence1336Statistical recurrence1336Statistical recurrence1436Statistical recurrence1336Statistical recurrence1336Statistical recurrence1336Statistical recurrence1436Statistical recurrence1536Statistical recurrence1536Statistical recurrence1418Statistical recurrence1418Statistical recurrence1536Statistical recurrence1536Statistical recurrence1610Statistical recurrence1818Statistical recurrence1818 </td <td>pT Stage</td> <td></td> <td></td> <td>1.24 (0.69–2.21)</td> <td>0.475</td> <td></td> <td></td>	pT Stage			1.24 (0.69–2.21)	0.475		
pT3-pT4 (1 2 7 (10, 47-2, 17) 0, 985 (10, 47, 47) 0, 985 (10, 47, 47) 0, 985 (10, 47, 47) 0, 985 (10, 47, 47) 0, 985 (10, 47) (10, 47, 47) 0, 985 (10, 47) (10, 47	pT2	48	39				
pNS stage 1.01 (0.47-2.17) 0.985 pN1 17 2 R Status 0.00 (0.34-1.43) 0.327 R Status 0.00 (0.34-1.43) 0.327 R Marcine 12 3 0 R Status 0.10 (0.37-1.52) 0.380 SUP Score 0.17 (0.33-1.52) 0.380 I-3 3 0 4-5 0.93 0 PSA persistence vs. PSA Recurrence 107 (0.59-1.95) 0.828 PSA persistence vs. PSA Recurrence 107 (0.59-1.95) 0.828 PSA before PET/CT 1.27 (0.72-2.25) 0.412 Status 1.3 0.030 PSA before PET/CT 1.27 (0.72-2.25) 0.412 Status 1.3 0.030 Caca Recurrence in PET/CT 1.27 (0.72-2.25) 0.412 Status 1.3 0.030 Caca Recurrence in PET/CT 1.27 (0.72-2.25) 0.412 Status 1.01 (0.56-1.84) 0.967 Status 1.01 (0.56-1.84) 0.14 (0.03-0.57) 0.007 </td <td>pT3 - pT4</td> <td>47</td> <td>27</td> <td></td> <td></td> <td></td> <td></td>	pT3 - pT4	47	27				
pN0f126pN11727R5atus0.70 (0.34-1.43)0.327R06430R1233ISUP Score0.71 (0.33-1.52)0.380ISUP Score0.71 (0.33-1.52)0.3801-383304.51937FSA persistence vs. PSA Recurrence937FSA recurrence6937FSA before PET/CT1.27 (0.72-2.52)0.4121 ag/m15337Local Recurrence in PET/CT0.93 (0.46-1.86)0.8361 ag/m15337Local Recurrence in PET/CT0.93 (0.46-1.86)0.8361 ag/m15337Local Recurrence in PET/CT0.93 (0.46-1.86)0.8361 ag/m151NCNC age to the Lymphatic Pathways1NCWobe pelvis RT0.20 (0.05-0.81)0.021Sto Gy1NCSto Gy128LNM Boost128LNM Boost128LNM Boost128RT of to LSM(EQD2 _{exp=1.5 Cy})500.049NC Go Gy5137So Gy609NT or to the Prostate Bed (EQD2 _{exp=1.5 Cy})7So Gy637So Gy79So Gy79NT or to the Prostate Bed (EQD2 _{exp=1.5 Cy})0.49So Gy609So Gy639So Gy79 </td <td>pN Stage</td> <td></td> <td></td> <td>1.01 (0.47–2.17)</td> <td>0.985</td> <td></td> <td></td>	pN Stage			1.01 (0.47–2.17)	0.985		
pNi 0,70 (0.34-1.43) 0.327 R Status 0.70 (0.34-1.43) 0.327 R (1 0.33 - 1.52) 0.30 R (1 0.55 - 1.53) 0.32 R (1 0.55 - 1.54) 0.53 R (1 0.55 - 1.54) 0.53 R (1 0.55 - 1.54) 0.56 R (1 0.55 - 1.54) 0.57 R (1 0.	pN0	71	36				
Rstatus0.70 (0.34-1.43)0.327R06430R12339ISUP Sore0.310.3101-330.71 (0.33-1.52)0.3804-5193PSA persistence vs.PSA Recurrence1037PSA persistence vs.PSA Recurrence107PSA persistence vs.PSA Recurrence107PSA persistence vs.PSA Recurrence1010.7 (0.59-1.95)0.828PSA bersistence vs.PSA Recurrence1010.7 (0.72-2.25)0.41210.11PSA bersitence vs.PSA Recurrence2010.27 (0.72-2.25)0.41210.11PSA bersitence vs.PSA Recurrence203610.1110.1110.11PSA bersitence vs.PSA Recurrence203610.1110.1110.11PSA bersitence vs.PSA Recurrence203610.1110.1110.1110.11PSA bersitence vs.PSA Recurrence203610.1110.1110.1110.1110.11PSA bersitence vs.PSA Recurrence1110.111	pN1	17	27				
R06430R1R139R1R1711-383304-58330PSA Persistence vs. PSA Recurrence10PSA persistence vs. PSA Recurrence30PSA recurrence PET/CT1.27 (0.72-2.25)0.412741 ag/ml750 afore PET/CT1.27 (0.72-2.25)0.412751 ag/ml761 ag/ml761 ag/ml761 ag/ml761 ag/ml761 ag/ml761 ag/ml761 ag/ml761 ag/ml861 ag/ml761 ag/ml861 ag/ml861 ag/ml861 ag/ml861 ag/ml870 forbel symphatic Pathways871 block of the Lymphatic Pathways (EQD2 ag/m = 15)71 block of the Lymphatic Pathways (EQD2 ag/m = 15)75 bG Gy871 block of LNM (EQD2 ag/m = 15)71 block of LNM (EQD2 ag/m = 15)72 ag/mather bed773 contract ag/mather bed1774 cort ag/mather bed774 cort ag/mather bed774 cort ag/mather bed775 cord ag/mather bed776 cord ag/mather bed777 cord ag/mather bed778 cord ag/mather bed779 cord ag/mather bed770 cord ag/mather bed774 cord prostate bed774 cord pr	R Status			0.70 (0.34–1.43)	0.327		
R1 23 39 ISUP Score 0.71 (0.33-1.52) 0.380 I-3 30 4-5 19 37 PSA persistence vs.PSA Recurrence 107 (0.59-1.95) 0.828 PSA persistence vs.PSA Recurrence 69 37 PSA recurrence 69 37 PSA fore PET/CT 1.27 (0.72-2.25) 0.412 > 1 ng/ml 5 37 Docal Recurrence in PET/CT 0.93 (0.46-1.86) 0.836 no local recurrence 20 37 Indiant Pethods 7 6 Indiant Pethods 7 0.93 (0.46-1.86) 0.836 Indiant Pethods 7 8 7 Indiant Pethods 101 (0.56-1.84) 0.967 1007 Sold recurrence 20 37 7 1007 Sold recurrence 10 101 (0.56-1.84) 0.967 1007 Sold recurrence 10 101 (0.56-1.84) 0.967 1007 Sold recurrence 10 101 (0.56-1.84) 0.967 0.002 Sold recurrence 10 <td< td=""><td>R0</td><td>64</td><td>30</td><td></td><td></td><td></td><td></td></td<>	R0	64	30				
ISUP Score 0.71 (0.33–1.52) 0.380 1–3 83 30 4–5 19 37 PSA persistence vs. PSA Recurrence 30 37 PSA persistence vs. PSA Recurrence 30 37 PSA recurrence 69 37 PSA before PET/CT 1.27 (0.72–2.25) 0.412 47 ≤ 1 ng/ml 75 37 Local Recurrence in PET/CT 0.93 (0.46–1.86) 0.836 5 local recurrence 82 37 local recurrence 82 36 local recurrence 82 36 local recurrence 82 36 local recurrence 81 N RT of te Lymphatic Pathways 51 36 RT base to the Lymphatic Pathways (EQD2 _{upl=15.6}) 50 G9 0.20 (0.05–0.81) 0.41 (0.03–0.57) 0.007 ≤ 50 G9 14 NR 1.11 (0.52–0.97) 0.40 (0.03–0.52) 0.002 RT Dose to LNM (EQD2 _{upl=1.5 Cy}) 51 36 1.8 (0.06–0.52) 0.002 RT of prostate bed	R1	23	39				
1-3 0 4-5 10 37 PSA Persistence vs. PSA Recurrence 10 37 PSA persistence 30 37 PSA recurrence 30 37 PSA recurrence 30 37 PSA recurrence 30 37 Sta ford PET/CT 1.27 (0.72-2.25) 0.412 Coal Recurrence in PET/CT 0.93 (0.46-1.86) 0.836 No local recurrence 82 36 Ical Recurrence in PET/CT 0.93 (0.46-1.86) 0.836 No local recurrence 82 36 Ical Recurrence 82 36 RT of the Lymphatic Pathways 51 NR RT bost the Lymphatic Pathways (EQD2 _{upl=1.5G}) 0.20 (0.05-0.81) 0.024 0.14 (0.03-0.57) 0.007 >50 Gy 14 NR NR NR NR NR NR NR LNM boost 12 8 NR NR NR NR NR NR S0 Gy 30 37 NR NR NR NR NR LNM boost	ISUP Score			0.71 (0.33–1.52)	0.380		
4-5	1–3	83	30				
PSA persistence vs. PSA Recurrence 107 (0.59–1.95) 0.828 PSA persistence 37 PSA recurrence 37 PSA before PET/CT 1.27 (0.72–2.25) 0.412 $\leq 1 ng/ml$ 7 $\geq 1 ng/ml$ 7 $\geq 1 ng/ml$ 7 $\geq 1 ng/ml$ 8 Local Recurrence in PET/CT 0.93 (0.46–1.86) 0.836 local recurrence 82 local recurrence 8 Store the Imphatic Pathways 8 RT Of the Lymphatic Pathways (EQD2 _{uep1-15 Gy}) 8 Sto Goy 14 NR Boost 0.20 (0.05–0.81) 0.024 0.14 (0.03–0.57) 0.007 ≤ 50 Gy 14 NR 1.1 (0.56–1.84) 0.18 (0.06–0.52) 0.002 ≤ 50 Gy 14 NR 1.1 (0.05–0.81) 0.024 0.14 (0.03–0.57) 0.007 ≤ 50 Gy 16 27 1.2 (0.14–0.75) 0.028 0.18 (0.06–0.52) 0.002 LNM Boost 12 8 1.1 (0.55–1.02) 0.18 (0.06–0.52) 0.002 RT Dose to LNM (EQD2 _{uep1.5 Gy}) 30	4–5	19	37				
PSA persistence 30 37 PSA recurrence 69 37 PSA before PLT/CT 1.27 (0.72–2.5) 0.412 > l ng/ml 5 37 Local Recurrence in PET/CT 0.93 (0.46–1.86) 0.836 no local recurrence 20 37 RT of te Lymphatic Pathways 100 0.93 (0.46–1.86) 0.836 whole pelvis RT 0.93 (0.46–1.86) 0.836 1 RT Dose to the Lymphatic Pathways (EQD2 _{avp=1.5 GV}) 1.01 (0.56–1.84) 0.967 ≤ 50 Gy 8 27 0.14 (0.03–0.57) 0.007 ≤ 50 Gy 8 27 0.18 (0.06–0.52) 0.002 > 50 Gy 8 27 0.18 (0.06–0.52) 0.002 > 50 Gy 8 2 0.18 (0.06–0.52) 0.002 > 10 LNM boost 9 37 2 2 0.18 (0.06–0.52) 0.002 < 60 Gy 37 37 2 2 2 2 2 2 0.18 (0.06–0.52) 0.002 0.002 0.18 (0.06–0.52) 0.002 0.18 (0.06–0.52) 0.002 0.18 (0.06–0.52) <td>PSA Persistence vs. PSA Recurrence</td> <td></td> <td></td> <td>1.07 (0.59–1.95)</td> <td>0.828</td> <td></td> <td></td>	PSA Persistence vs. PSA Recurrence			1.07 (0.59–1.95)	0.828		
PSA recurrence 69 37 PSA before PET/CT $1.27 (0.72-2.25)$ 0.412 $\leq 1 ng/ml$ 50 37 Local Recurrence in PET/CT $0.93 (0.46-1.86)$ 0.836 no local recurrence 82 36 local recurrence 82 36 Rot othe Lymphatic Pathways 12 NR show pelvis RT 51 NR show pelvis RT 51 36 St Dose to the Lymphatic Pathways (EQD2 _{upl=L5Gy}) 62 $0.20 (0.05-0.81)$ 0.024 $0.14 (0.03-0.57)$ 0.007 $\leq 50 Gy$ KT $0.20 (0.05-0.81)$ 0.024 $0.14 (0.03-0.57)$ 0.007 $\leq 50 Gy$ KT NR $0.20 (0.05-0.81)$ 0.024 $0.14 (0.03-0.57)$ 0.007 $\leq 50 Gy$ KT NR $0.20 (0.14-0.75)$ 0.008 $0.18 (0.06-0.52)$ 0.002 $\sim 150 Gy$ I NR $0.014 (0.03-0.57)$ 0.002 0.024 $0.14 (0.03-0.57)$ 0.002 $< 10 INM boost$ I NR I $0.020 (0.14-0.75)$ 0.008 $0.18 (0.06-0.52)$ <td>PSA persistence</td> <td>30</td> <td>37</td> <td></td> <td></td> <td></td> <td></td>	PSA persistence	30	37				
PSA before PET/CT 1.27 ($0.72-2.25$) 0.412 $\leq 1 ng/ml$ 7 36 > $l ng/ml$ 50 7 $> l ng/ml$ 60 93 0.836 $> l ng/ml$ 80 0.836 1000 no local recurrence in PET/CT 0.93 ($0.46-1.86$) 0.836 1000 no local recurrence 82 36 1000<	PSA recurrence	69	37				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	PSA before PET/CT			1.27 (0.72–2.25)	0.412		
> 1 ng/ml 55 37 Local Recurrence in PET/CT 0.93 (0.46-1.86) 0.836 no local recurrence 20 36 local recurrence 20 37 RT of the Lymphatic Pathways 1.01 (0.56-1.84) 0.967 hemi pelvis RT 51 36 RT Dose to the Lymphatic Pathways (EQD2 _{ω/β} -1.56) 36 0.220 (0.05-0.81) 0.024 0.14 (0.03-0.57) 0.007 ≤ 50 Gy K1 36 27 0.32 (0.14-0.75) 0.008 0.18 (0.06-0.52) 0.002 s 50 Gy K1 NR 28 28 28 28 29 0.008 0.18 (0.06-0.52) 0.002 ND Moost L NB 37 37 37 37 36 37 ≤ 60 Gy S 7 37 37 38 38 38 38 38 RT fore to LNM (EQD2 _{α/β=1.5 Gy}) S 37 37 37 37 37 S 60 Gy S 37 S 37 37 37 38 <th< td=""><td>$\leq 1 \text{ ng/ml}$</td><td>47</td><td>36</td><td></td><td></td><td></td><td></td></th<>	$\leq 1 \text{ ng/ml}$	47	36				
Local Recurrence in PET/CT $0.93 (0.46-1.86)$ 0.836 no local recurrence 2 36 local recurrence 2 36 RT of the Lymphatic Pathways $101 (0.56-1.84)$ 0.967 hemi pelvis RT 51 R whole pelvis RT 51 R RT Dots to the Lymphatic Pathways (EQD2 _{<math>w\beta=1.56) V $0.020 (0.05-0.81)$ 0.024 $0.14 (0.03-0.57)$ 0.007 $\leq 50 Gy$ 62 27 $0.025 (0.14-0.75)$ 0.008 $0.18 (0.06-0.52)$ 0.002 $> 50 Gy$ 14 R <td< sub=""></td<></math>}	>1 ng/ml	55	37				
no local recurrence 82 36 local recurrence 20 37 RT ofte Lymphatic Pathways 1.01 (0.56-1.84) 0.967 hemi pelvis RT 51 36 RT Dose to the Lymphatic Pathways (EQD2 _{a/β=1.5 G}) 0.20 (0.05-0.81) 0.024 0.14 (0.03-0.57) 0.007 ≤50 Gy 48 2 1.10 (0.56-1.84) 0.024 0.14 (0.03-0.57) 0.007 ≤50 Gy 48 2 1.10 (0.56-1.84) 0.024 0.14 (0.03-0.57) 0.007 ≤50 Gy 18 2 1.10 (0.56-1.84) 0.024 0.18 (0.06-0.52) 0.002 S0 Gy 18 N 1.10 (0.56-1.84) 0.008 0.18 (0.06-0.52) 0.002 ND NB boost 12 8 1.10 (0.05-0.91) 0.008 0.18 (0.06-0.52) 0.002 S0 Gy 50 37 37 1.10 (0.55-0.02) 0.404 0.89 (0.38-2.08) 0.783 S0 Gy 57 37 1.10 (0.52-0.97) 0.404 0.89 (0.38-2.08) 0.783 RT of prostate bed	Local Recurrence in PET/CT			0.93 (0.46–1.86)	0.836		
local recurrence 20 37 RT ofte Lymphatic Pathways Interpret in the second	no local recurrence	82	36				
RT of the Lymphatic Pathways 51 NR hemi pelvis RT 51 NR RT Dose to the Lymphatic Pathways (EQD2 $_{a/\beta}=1.5$ (GOV) 0.20 (0.05-0.81) 0.02 0.14 (0.03-0.57) 0.007 ≤ 50 Gy 8 2 0.20 (0.05-0.81) 0.024 0.14 (0.03-0.57) 0.007 ≤ 50 Gy 14 NR 0.20 (0.05-0.81) 0.024 0.14 (0.03-0.57) 0.002 > 50 Gy 14 NR 1 NR 1	local recurrence	20	37				
hemi pelvis RT515151whole pelvis RT5136RT Dose to the Lymphatic Pathways (EQD2 $_{u/\beta=1.5 GV}$)8627 ≤ 50 Gy8627>50 Gy188LNM Boost0.32 (0.14-0.75)0.080.18 (0.06-0.52)0.002no LNM boost9037RT Dose to LNM (EQD2 $_{u/\beta=1.5 GV}$)9037	RT of the Lymphatic Pathways			1.01 (0.56–1.84)	0.967		
whole pelvis RT 51 36 RT Dose to the Lymphatic Pathways (EQD2 $_{u/\beta=1.5 Gy}$) 6 27 $\leq 50 Gy$ 86 27 $> 50 Gy$ 14 NR LNM Boost 12 8 LNM boost 12 8 LNM boost 12 8 RT Dose to LNM (EQD2 $_{u/\beta=1.5 Gy}$) 0.32 (0.14-0.75) 0.008 0.18 (0.06-0.52) 0.002 $\leq 60 Gy$ 70 37 7 7 7 7 7 $RT of Prostate Bed$ 70 37 7 7 7 7 7 RT of prostate bed 17 12 8 8 7 8 7 7 RT of prostate bed 17 12 7 12 8 8 7 7 7 RT of prostate bed 17 12 13 12 12	hemi pelvis RT	51	NR				
RT Dose to the Lymphatic Pathways (EQD2 $_{a/\beta=1.5 \text{ Gy}}$) 0.20 (0.05–0.81) 0.024 0.14 (0.03–0.57) 0.007 $\leq 50 \text{ Gy}$ 14 NR $>50 \text{ Gy}$ 14 NR LNM Boost 12 8 ND boost 12 8 INM boost 90 37 RT Dose to LNM (EQD2 $_{a/\beta=1.5 \text{ Gy}}$) 0.60 (0.31–1.19) 0.143 $\leq 60 \text{ Gy}$ 57 37 $>60 \text{ Gy}$ 30 37 RT of prostate Bed 17 12 RT of prostate Bed 17 12 RT of prostate Bed 17 12 RT of prostate Bed (EQD2 $_{a/\beta=1.5 \text{ Gy}$) 0.51 (0.25–0.97) 0.040 0.89 (0.38–2.08) 0.783 red G Gy 17 12 12 RT of prostate Bed (EQD2 $_{a/\beta=1.5 \text{ Gy}}$) 0.51 (0.25–1.02) 0.058 10.03 $< 66 \text{ Gy}$ 44 NR 10.00000000000000000000000000000000000	whole pelvis RT	51	36				
$ \begin{array}{c c c c c c c c c } \leq 50 \ Gy & 14 & 86 & 27 \\ > 50 \ Gy & 14 & NR \\ \hline LNM Boost & 0.32 (0.14-0.75) & 0.008 & 0.18 (0.06-0.52) & 0.002 \\ no LNM boost & 12 & 8 \\ LNM boost & 90 & 37 \\ \hline RT Dose to LNM (EQD2_{\alpha\beta=1.5 \ Gy}) & 0.60 (0.31-1.19) & 0.143 \\ \leq 60 \ Gy & 57 & 37 \\ > 60 \ Gy & 30 & 37 \\ \hline RT of prostate Bed & & & & & & & & & & & & & \\ no RT of prostate bed & & 17 & 12 \\ RT of prostate bed & & 17 & 12 \\ RT of prostate bed & & & & & & & & & & & & & & & & & & \\ rt of prostate bed & & & & & & & & & & & & & & & & & & &$	RT Dose to the Lymphatic Pathways (EQD2 _{$\alpha/B=1.5$ Gy)}			0.20 (0.05–0.81)	0.024	0.14 (0.03–0.57)	0.007
$> 50 \text{ Gy}$ 14NRLNM Boost12 $0.32 (0.14-0.75)$ 0.008 $0.18 (0.06-0.52)$ 0.002 no LNM boost128LNM boost90 37 $0.60 (0.31-1.19)$ 0.143 $\leq 60 \text{ Gy}$ 57 37 $> 60 \text{ Gy}$ 50 37 $> 60 \text{ Gy}$ 57 37 $> 60 \text{ Gy}$ $60 (0.31-1.19)$ 0.143 $> 60 \text{ Gy}$ 57 37 $> 60 \text{ Gy}$ $60 (0.38-2.08)$ 0.783 $> 60 \text{ Gy}$ 57 37 RT of prostate Bed $(EQD2_{\alpha/\beta=1.5 \text{ Gy})}$ $0.49 (0.25-0.97)$ 0.040 $0.89 (0.38-2.08)$ 0.783 $> 10 \text{ Borstate Bed}$ 71 12 RT of prostate Bed (EQD2_{\alpha/\beta=1.5 \text{ Gy}}) $0.51 (0.25-1.02)$ 0.058 -12 Borstate Bed <th< td=""><td>≤50 Gy</td><td>86</td><td>27</td><td></td><td></td><td></td><td></td></th<>	≤50 Gy	86	27				
LNM Boost 0.32 (0.14–0.75) 0.008 0.18 (0.06–0.52) 0.002 no LNM boost 12 8 12 13 13 13 14 1	>50 Gy	14	NR				
no LNM boost 12 8 LNM boost 90 37 RT Dose to LNM (EQD2 $_{\alpha/\beta=1.5 \text{ Gy}}$) 0.60 (0.31–1.19) 0.143 $\leq 60 \text{ Gy}$ 57 37 > 60 Gy 30 37 RT of Prostate Bed 0.49 (0.25–0.97) 0.040 0.89 (0.38–2.08) 0.783 no RT of prostate bed 17 12 17 12 RT of prostate bed 17 12 0.51 (0.25–1.02) 0.058 < 66 Gy	LNM Boost			0.32 (0.14-0.75)	0.008	0.18 (0.06-0.52)	0.002
LNM boost 90 37 RT Dose to LNM (EQD2 $_{u/\beta=1.5 \text{ Gy}}$) 0.60 (0.31–1.19) 0.143 ≤ 60 Gy 57 37 > 60 Gy 30 37 RT of Prostate Bed 0.49 (0.25–0.97) 0.040 0.89 (0.38–2.08) 0.783 no RT of prostate bed 17 12 RT of prostate Bed (EQD2 $_{u/\beta=1.5 \text{ Gy}}$) 0.51 (0.25–1.02) 0.058 < 66 Gy	no LNM boost	12	8				
RT Dose to LNM (EQD2 $_{\alpha/\beta=1.5 \text{ Gy}}$) 0.60 (0.31–1.19) 0.143 $\leq 60 \text{ Gy}$ 57 37 >60 Gy 30 37 RT of Prostate Bed 0.49 (0.25–0.97) 0.040 0.89 (0.38–2.08) 0.783 no RT of prostate bed 17 12 12 12 12 12 12 12 12 12 14 17 12 14 17 12 14 14 15 15 15 15 16 17 12 15 16 17 12 15 16 17 12 17 12 17 12 16 17 12 17 12 17 12 17 12 17 12 17 17 17 17 17 17 10 11 11 11 11 11 11 11 11 11 11 11 11 12 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 <td< td=""><td>LNM boost</td><td>90</td><td>37</td><td></td><td></td><td></td><td></td></td<>	LNM boost	90	37				
$ \leq 60 \text{ Gy} & 57 37 \\ > 60 \text{ Gy} & 30 37 \\ \textbf{RT of Prostate Bed} & 0.49 (0.25-0.97) 0.040 0.89 (0.38-2.08) 0.783 \\ no RT of prostate bed & 17 12 \\ RT of prostate bed & 85 37 \\ \textbf{RT Dose to the Prostate Bed (EQD2_{\alpha/\beta=1.5 \text{ Gy}}) & 0.51 (0.25-1.02) 0.058 \\ < 66 \text{ Gy} & 44 \text{ NR} \\ \geq 66 \text{ Gy} & 41 37 \\ \textbf{Concomitant ADT} & 0.34 (0.16-0.72) 0.005 0.29 (0.13-0.65) 0.003 \\ no \text{ ADT} & 71 27 \\ \text{ ADT} & 31 \text{ NR} \\ \textbf{Duration of ADT} & 1.81 (0.45-7.27) 0.401 \\ \leq 12 \text{ months} & 19 \text{ NR} \\ > 12 \text{ months} & 11 \text{ NR} \\ \end{cases} $	RT Dose to LNM (EQD2 _{$a/B-15Gy)$}			0.60 (0.31-1.19)	0.143		
>60 Gy 30 37 RT of Prostate Bed 0.49 (0.25–0.97) 0.040 0.89 (0.38–2.08) 0.783 no RT of prostate bed 17 12 RT of prostate bed 85 37 RT Dose to the Prostate Bed (EQD2 $_{\alpha/\beta=1.5 \text{ Gy}}$) 0.51 (0.25–1.02) 0.058 < 66 Gy	≤60 Gy	57	37				
RT of Prostate Bed $0.49 (0.25-0.97)$ 0.040 $0.89 (0.38-2.08)$ 0.783 no RT of prostate bed1712RT of prostate bed8537RT Dose to the Prostate Bed (EQD2 _{a/β=1.5 Gy}) $0.51 (0.25-1.02)$ 0.058 < 66 Gy	>60 Gy	30	37				
no RT of prostate bed 17 12 RT of prostate bed 85 37 RT Dose to the Prostate Bed (EQD2 _{α/β=1.5 Gy}) 0.51 (0.25–1.02) 0.058 <66 Gy	RT of Prostate Bed			0.49 (0.25–0.97)	0.040	0.89 (0.38-2.08)	0.783
RT of prostate bed 85 37 RT Dose to the Prostate Bed (EQD2 _{a/β=1.5 Gy}) $0.51 (0.25-1.02) 0.058$ < 66 Gy	no RT of prostate bed	17	12	· · · · · ·		. ,	
RT Dose to the Prostate Bed (EQD2 $_{\alpha/\beta=1.5 \text{ Gy}}$) 0.51 (0.25-1.02) 0.058 $< 66 \text{ Gy}$ 44 NR $\geq 66 \text{ Gy}$ 41 37 Concomitant ADT 0.34 (0.16-0.72) 0.005 0.29 (0.13-0.65) no ADT 71 27 ADT 31 NR Duration of ADT 181 (0.45-7.27) 0.401 ≤ 12 months 19 NR > 12 months 11 NR	RT of prostate bed	85	37				
<66 Gy 44 NR ≥66 Gy 41 37 Concomitant ADT no ADT ADT Duration of ADT 512 months 11 NR 11 NR 66 Gy 44 NR 66 Gy 60 Gy 6	RT Dose to the Prostate Bed (EOD2 $_{n/2-1.5}$ Cm)			0.51 (0.25–1.02)	0.058		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	<66 Gv	44	NR				
Concomitant ADT 0.34 (0.16-0.72) 0.005 0.29 (0.13-0.65) 0.003 no ADT 71 27 ADT 31 NR Duration of ADT 1.81 (0.45-7.27) 0.401 ≤ 12 months 19 NR > 12 months 11 NR	>66 Gy	41	37				
no ADT 71 27 ADT 31 NR Duration of ADT 1.81 (0.45–7.27) 0.401 ≤ 12 months 19 NR > 12 months 11 NR	Concomitant ADT			0.34 (0.16-0.72)	0.005	0.29 (0.13-0.65)	0.003
ADT 31 NR Duration of ADT 1.81 (0.45-7.27) 0.401 ≤ 12 months 19 NR > 12 months 11 NR	no ADT	71	27	- (. (
Duration of ADT 1.81 (0.45-7.27) 0.401 ≤ 12 months 19 NR > 12 months 11 NR	ADT	31	NR				
\leq 12 months 19 NR > 12 months 11 NR	Duration of ADT			1.81 (0.45-7.27)	0.401		
> 12 months 11 NR	<12 months	19	NR				
	> 12 months	11	NR				

applied as in the prospective OLIGOPELVIS GETUG P07 trial using a SIB concept to LNM of 66 Gy in 30 fractions [15].

Of course, there are several limitations of this analysis. First, the retrospective and multi-institutional character of the dataset leads to heterogenous diagnostic and therapeutic procedures. For example, there were no standardized PET/ CT protocols, no standardized recommendations for the use of ADT and no standardized contouring templates or RT dose prescriptions. Second, there were still differences in some of the patients' and treatment characteristics (dose of LNM boost, PSA recurrence vs. PSA persistence, additional local recurrence) and the median follow-up. Even if univariate analysis showed that none of these parameters had a significant influence on the outcome in this dataset (see Table 2), PSA persistence in general is known to predict BRFS, MFS and OS [30, 31]. Furthermore, the combination of PSA persistence and LNM in PSMA-PET/CT can be regarded as synchronous metastatic disease having a worse prognosis than metachronous metastatic disease [32]. These factors limit the comparability of the WPRT and HPRT group as the WPRT group may have been at a higher risk for further progression.

Third, the dataset did not include some relevant information like the number of LNM or the pattern of LNM distribution (uni- vs. bilateral) which may have had an influence on the treatment decision of the treating physician. It is possible that the treating physicians opted for WPRT in the case of bilateral or multiple LNM, so that there could be a tendency to find more patients with high-risk factors in the WPRT group. Other relevant information was not complete in this dataset. For example, information regarding the pN status, the R status and the RT dose to LNM are missing in approx. 15% of the patients. Moreover, the duration of ADT, which is known to predict BRFS in locally advanced patients [33] or MFS in the salvage situation [34], is missing for more than two thirds of patients. Therefore, it is possible that the results of this study are biased by different ADT durations in both groups.

The intention of treating only the unilateral lymphatic pathways is to reduce the radiation volume and thus to reduce toxicity. Unfortunately, due to the retrospective and multi-institutional character of this analysis without standardized documentation of toxicity the dataset did not include this data. The SPPORT trial showed that adding WPRT to prostate bed RT+ADT increased the acute toxicity (CTCAE °2 or higher) from 37.7 to 44.6% but did not increase late toxicity [25]. The PEACE V-STORM trial did not observe any differences in acute toxicity (CTCAE °2 or higher) or quality of life (QoL) between MDT (sLND or SBRT)+ADT and MDT+ADT+WPRT [26]. In a retrospective multi-institutional comparison SBRT patients had less acute (3.0% vs. 0.3%) and late (1.0% vs. 10.5%) toxicity (°2 or higher) than elective nodal RT patients [16]. Nevertheless, with regard to toxicity there is no sufficient prospective data to compare SBRT and WPRT and, to our knowledge, no data to compare HPRT and WPRT with regard to their toxicity.

When interpreting the outcome of PSMA-PET/CTguided RT also the limitations of PSMA-PET/CT have to be taken into account. Despite being the most advanced prostate cancer image modality the correlation of PSMA-PET/CT results with histopathological results revealed a sensitivity of only 40% in detecting LNM prior to pelvic lymph node dissection [35]. Thus, shrinking RT volumes has always the risk of missing more PSMA-PET/CT-occult LNM.

An interesting topic for future research is the metastasizing routes of LNM in PC patients. In the definitive setting there is evidence that 30-40% of nodal positive patients had LNM on the contralateral side of the dominant intraprostatic lesion [36] so that lymph node dissection or elective nodal RT is ideally performed bilaterally. In the postoperative setting with its changed lymphatic drainage there is no clear evidence about risk factors for bilateral lymphatic spread. After definitive prostate-only RT, failure pattern analyses showed that 55% of patients developing pelvic nodal recurrences had a common iliac involvement and 28% of patients had involvement of only one lymph node station. Risk factors for common iliac involvement were omission of ADT and a T3 stage [37]. All in all, defining subgroups of patients being appropriate candidates for a reduction of RT volumes like HPRT and also SBRT should be aimed. For this process it would be interesting to establish also risk factors for bilateral spread.

Furthermore, it will be also necessary to look beyond the local and radiotherapeutic treatment options. The EMBARK trial showed that a combination of enzalutamide and ADT in high-risk recurrent PC patients (PSA doubling time≤9 months) led to a better MFS than ADT alone or enzalutamide alone. However, patients in this trial did not receive RT [38]. In a retrospective analysis of the STAMPEDE platform in primary and relapsed PC patients with LNM or other highrisk features adding abiraterone and prednisolone to standard of care improved MFS. However, in this analysis only 1-2% of the relapsed patients had LNM and pelvic RT was not part of the therapy [39]. Two phase II trials showed that adding enzalutamide to salvage RT of the prostate bed was safe and led to encouraging results in patients with high-risk biochemical recurrence. However, in these trials patients with (large) LNM were excluded and pelvic RT was not allowed [40, 41]. Altogether, further research is required to determine the role of advanced ADT and its combination with RT in patients with nodal recurrence.

Conclusions

The present retrospective analysis compared the outcome of HPRT and WPRT in patients with PSMA-positive LNM recurrences after prostatectomy. Furthermore, it is the first report of HPRT results in PC patients. Despite using propensity score matching there were still imbalances between both groups and patients of the WPRT group may have been at a higher risk for further progression than patients in the HPRT group. All in all, no significantly different results were observed in both groups and results were favorable overall (2-yr BRFS approximately 60% in both groups). Concomitant ADT, RT dose to the pelvic lymphatics and application of a LNM boost were significant predictors of BRFS. Other radiotherapeutic approaches (SBRT or WPRT) will remain preferred treatment options due to better evidence. Nevertheless, this analysis shows that HPRT for selected favorable risk patients deserves further research including long-term follow-up, prospective trials and evaluation of toxicity and quality of life.

Abbreviations

ADT	Androgen deprivation therapy
BRFS	Biochemical recurrence-free survival
CI	Confidence interval
EQD2	Equivalent dose in 2 Gy fractions
HPRT	Hemi pelvis radiotherapy
HR	Hazard ratio
ISUP	International society of urological
	pathology
LNM	Lymph node metastasis
MDT	Metastasis directed therapy
MFS	Metastasis-free survival
NRFS	Nodal recurrence-free survival
NR	Not reached
PFS	Progression free-survival
PC	Prostate cancer
PSA	Prostate-specific antigen
PSMA-PET/CT	Prostate-specific membrane antigen-
	positron emission tomography/com-
	puted tomography
RT	Radiotherapy
sLND	Salvage lymph node dissection
SIB	Simultaneous integrated boost
SBRT	Stereotactic body radiotherapy

Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript. Open Access funding enabled and organized by Projekt DEAL.

Data availability The datasets generated analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethical approval This multi-institutional retrospective analysis followed the "Strengthening the Reporting of Observational Studies in Epidemiology" (STROBE) reporting guideline. It was approved by local ethics committees of all participating centers (University of Freiburg, Freiburg, Germany; University of Munich, Munich, Germany; Technical University of Munich, Munich, Germany; University of Bologna, Bologna, Italy; University of Ulm, Ulm, Germany; Ethics Committee Zuerich, Zuerich, Switzerland; University of New South Wales, Sydney, Australia; University of Heidelberg, Heidelberg, Germany; Cyprus National Bioethics Committee, Nicosia, Cyprus; Cantonal Ethics Commission Bern, Bern, Switzerland).

Consent to participate Written informed consent was waived due to the retrospective character of the study.

Competing interests Stefano Fanti is member of the editorial board of this journal. All other authors have no relevant financial or non-financial interests to disclose.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer [eng]. J Urol. 2003. https://doi.org/10.1097/01. ju.0000045749.90353.c7.
- Roehl KA, Han M, Ramos CG, Antenor JAV, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results [eng]. J Urol. 2004. https://doi.org/10.1097/01.ju.0000134888.22332.bb.
- Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, et al. 68Ga-PSMA-11 PET/CT mapping of prostate Cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA Level of Less Than 1.0 ng/mL: impact on Salvage Radiotherapy Planning [eng]. J Nucl Med. 2018. https://doi. org/10.2967/jnumed.117.201749.
- Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, et al. Salvage stereotactic body radiotherapy for isolated Lymph Node recurrent prostate Cancer: single Institution Series of 94 consecutive patients and 124 lymph nodes [eng]. Clin Genitourin Cancer. 2017. https://doi.org/10.1016/j. clgc.2017.01.004.
- Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, et al. Stereotactic body radiotherapy for oligometastatic prostate Cancer detected via prostate-specific membrane Antigen Positron Emission Tomography [eng]. Eur Urol Oncol. 2018. https://doi. org/10.1016/j.euo.2018.04.017.
- Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, de Bruycker A, et al. Surveillance or Metastasis-Directed therapy for oligometastatic prostate Cancer recurrence: a prospective, randomized, Multicenter Phase II trial [eng]. JCO. 2018. https:// doi.org/10.1200/JCO.2017.75.4853.
- Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for oligometastatic prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial [eng]. JAMA Oncol. 2020. https://doi. org/10.1001/jamaoncol.2020.0147.

- Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): extended long-term outcomes [eng]. Int J Radiat Oncol Biol Phys. 2022. https://doi. org/10.1016/j.ijrobp.2022.05.004.
- Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic abative body Radiotherapy (SABR) for oligometastatic prostate Cancer: a prospective clinical trial [eng]. Eur Urol. 2018. https://doi.org/10.1016/j.eururo.2018.06.004.
- Deek MP, van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-term outcomes and genetic predictors of response to Metastasis-Directed Therapy Versus Observation in oligometastatic prostate Cancer: analysis of STOMP and ORI-OLE trials [eng]. J Clin Oncol. 2022. https://doi.org/10.1200/ JCO.22.00644.
- Tran S, Jorcano S, Falco T, Lamanna G, Miralbell R, Zilli T. Oligorecurrent nodal prostate Cancer: long-term results of an Elective nodal Irradiation Approach [eng]. Am J Clin Oncol. 2018. https:// doi.org/10.1097/COC.00000000000419.
- Fodor A, Berardi G, Fiorino C, Picchio M, Busnardo E, Kirienko M, et al. Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer [eng]. BJU Int. 2017. https://doi.org/10.1111/bju.13510.
- Rogowski P, Trapp C, von Bestenbostel R, Eze C, Ganswindt U, Li M, et al. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy [eng]. Eur J Nucl Med Mol Imaging. 2022. https://doi.org/10.1007/ s00259-021-05557-z.
- Tamihardja J, Zehner L, Hartrampf P, Lisowski D, Kneitz S, Cirsi S, et al. Salvage nodal Radiotherapy as Metastasis-Directed therapy for oligorecurrent prostate Cancer detected by Positron Emission Tomography shows favorable outcome in Long-Term Follow-Up [eng]. Cancers (Basel). 2022. https://doi.org/10.3390/ cancers14153766.
- Supiot S, Vaugier L, Pasquier D, Buthaud X, Magné N, Peiffert D, et al. OLIGOPELVIS GETUG P07, a Multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in Oligorecurrent pelvic node relapses in prostate Cancer [eng]. Eur Urol. 2021. https://doi.org/10.1016/j.eururo.2021.06.010.
- de Bleser E, Jereczek-Fossa BA, Pasquier D, Zilli T, van As N, Siva S, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate Cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy [eng]. Eur Urol. 2019. https://doi. org/10.1016/j.eururo.2019.07.009.
- de Bruycker A, Spiessens A, Dirix P, Koutsouvelis N, Semac I, Liefhooghe N, et al. PEACE V - salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): a study protocol for a randomized controlled phase II trial [eng]. BMC Cancer. 2020. https://doi.org/10.1186/s12885-020-06911-4.
- Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, et al. Patterns of Progression after 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for recurrent prostate Cancer [eng]. Int J Radiat Oncol Biol Phys. 2019. https://doi. org/10.1016/j.ijrobp.2018.08.066.
- Fodor A, Brombin C, Deantoni CL, Giannini L, Ferrario F, Villa SL, et al. Extended nodal radiotherapy for prostate cancer relapse guided with [11 C]-choline PET/CT: ten-year results in patients enrolled in a prospective trial. Eur J Nucl Med Mol Imaging. 2024. https://doi.org/10.1007/s00259-023-06445-4.
- Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, et al. Development and validation of a multi-institutional Nomogram of outcomes for PSMA-PET-Based salvage radiotherapy for recurrent prostate

Cancer [eng]. JAMA Netw Open. 2023. https://doi.org/10.1001/jamanetworkopen.2023.14748.

- Cozzi S, Botti A, Timon G, Blandino G, Najafi M, Manicone M, et al. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer: an investigation of 117 pelvic lymph nodes. Strahlenther Onkol. 2022. https://doi.org/10.1007/ s00066-021-01871-5.
- Cuccia F, Tamburo M, Piras A, Mortellaro G, Iudica A, Daidone A, et al. Stereotactic body radiotherapy for lymph-nodal oligometastatic prostate Cancer: a Multicenter Retrospective experience [eng]. Med (Kaunas). 2023. https://doi.org/10.3390/ medicina59081442.
- Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D'agostino G, et al. Rezidivmuster Nach Stereotaktischer Radiotherapie beim oligometastasierten Prostatakarzinom: eine multiinstitutionelle Analyse. [Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis] [eng]. Strahlenther Onkol. 2020. https://doi. org/10.1007/s00066-019-01523-9.
- Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, et al. NRG Oncology Updated International Consensus Atlas on pelvic lymph node volumes for Intact and postoperative prostate Cancer [eng]. Int J Radiat Oncol Biol Phys. 2021. https:// doi.org/10.1016/j.ijrobp.2020.08.034.
- Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022. https://doi. org/10.1016/S0140-6736(21)01790-6.
- Ost P, Siva S, Brabrand S, Dirix P, Liefhooghe N, Otte F-X, et al. PEACE V-Salvage treatment of OligoRecurrent nodal prostate cancer metastases (STORM): Acute Toxicity of a Randomized phase 2 trial [eng]. Eur Urol Oncol. 2023. https://doi. org/10.1016/j.euo.2023.09.007.
- Pommier P, Chabaud S, Lagrange J-L, Richaud P, Le Prise E, Wagner J-P, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study [eng]. Int J Radiat Oncol Biol Phys. 2016. https://doi.org/10.1016/j.ijrobp.2016.06.2455.
- Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, et al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial [eng]. Lancet Oncol. 2018. https://doi.org/10.1016/ S1470-2045(18)30528-X.
- Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G, et al. Prostate-only Versus Whole-Pelvic Radiation Therapy in High-Risk and very high-risk prostate Cancer (POP-RT): outcomes from phase III randomized controlled trial [eng]. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.20.03282.
- Preisser F, Incesu R-B, Rajwa P, Chlosta M, Nohe F, Ahmed M, et al. Impact of persistent PSA after salvage radical prostatectomy: a multicenter study [eng]. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-023-00728-5.
- Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, et al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96–02 trial [eng]. Int J Radiat Oncol Biol Phys. 2015. https://doi.org/10.1016/j. ijrobp.2014.09.039.
- 32. Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B et al. Time of Metastatic Disease Presentation and Volume of Disease are Prognostic for Metastatic Hormone Sensitive Prostate

Cancer (mHSPC) [eng]. Prostate. 2018; https://doi.org/10.1002/pros.23645.

- Cuppone F, Bria E, Giannarelli D, Vaccaro V, Milella M, Nisticò C, et al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: metaanalysis of randomized trials. BMC Cancer. 2010. https://doi. org/10.1186/1471-2407-10-675.
- 34. Parker CC, Clarke N, Cook A, Catton C, Cross WR, Kynaston H, et al. LBA9 duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031). Ann Oncol. 2022. https://doi.org/10.1016/j.annonc.2022.08.064.
- 35. Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial [eng]. JAMA Oncol. 2021. https://doi. org/10.1001/jamaoncol.2021.3771.
- Tokuda Y, Carlino LJ, Gopalan A, Tickoo SK, Kaag MG, Guillonneau B, et al. Prostate cancer topography and patterns of lymph node metastasis [eng]. Am J Surg Pathol. 2010. https://doi. org/10.1097/PAS.0b013e3181fc679e.
- Spratt DE, Vargas HA, Zumsteg ZS, Golia Pernicka JS, Osborne JR, Pei X, et al. Patterns of Lymph Node Failure after dose-escalated Radiotherapy: implications for extended pelvic lymph Node Coverage [eng]. Eur Urol. 2017. https://doi.org/10.1016/j.eururo.2016.07.043.

- Freedland SJ, de Almeida Luz M, de Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with Enzalutamide in biochemically recurrent prostate Cancer [eng]. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa2303974.
- 39. Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol [eng]. Lancet. 2022. https://doi.org/10.1016/S0140-6736(21)02437-5.
- 40. Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, et al. Phase II trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in men with high-risk prostate-specific Antigen recurrent prostate Cancer: the STREAM trial [eng]. Eur Urol Oncol. 2021. https://doi.org/10.1016/j.euo.2020.01.005.
- 41. Tran PT, Lowe K, Tsai H-L, Song DY, Hung AY, Hearn JWD, et al. Phase II randomized study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk prostate-specific Antigen recurrent prostate Cancer after Radical Prostatectomy: the SALV-ENZA trial [eng]. J Clin Oncol. 2023. https://doi.org/10.1200/ JCO.22.01662.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Christian Trapp¹ · Daniel M. Aebersold² · Claus Belka^{1,3} · Jozefina Casuscelli⁴ · Louise Emmett^{5,6} · Chukwuka Eze¹ · Stefano Fanti⁷ · Andrea Farolfi⁷ · Wolfgang Fendler⁸ · Anca-Ligia Grosu^{9,10} · Matthias Guckenberger¹¹ · George Hruby¹² · Simon Kirste⁹ · Stefan A. Koerber^{13,14} · Stephanie Kroeze¹¹ · Jan C. Peeken^{3,15} · Paul Rogowski¹ · Sophia Scharl¹⁶ · Mohamed Shelan² · Simon K. B. Spohn^{9,10,17} · Iosif Strouthos¹⁸ · Lena Unterrainer^{19,20} · Marco Vogel^{3,15} · Thomas Wiegel¹⁶ · Constantinos Zamboglou^{9,10,18} · Nina-Sophie Schmidt-Hegemann¹

Christian Trapp christian.trapp@med.uni-muenchen.de

- ¹ Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
- ² Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- ³ Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany
- ⁴ Department of Urology, University Hospital, LMU Munich, Munich, Germany
- ⁵ Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia
- ⁶ St. Vincent's Clinical School, University of New South Wales, Sydney, Australia
- ⁷ Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- ⁸ Department of Nuclear Medicine, University Hospital, University of Essen, Essen, Germany
- ⁹ Department of Radiation Oncology, Medical Center, University of Freiburg, Freiburg, Germany
- ¹⁰ Deutsches Konsortium f
 ür Translationale Krebsforschung (DKTK), Partner Site Freiburg, Freiburg, Germany

- ¹¹ Department of Radiation Oncology, University Hospital, University of Zurich, Zurich, Switzerland
- ¹² Department of Radiation Oncology, Royal North Shore Hospital, University of Sydney, Sydney, Australia
- ¹³ Department of Radiation Oncology, Barmherzige Brüder Hospital Regensburg, Regensburg, Germany
- ¹⁴ Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany
- ¹⁵ Department of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany
- ¹⁶ Department of Radiation Oncology, University of Ulm, Ulm, Germany
- ¹⁷ Berta-Ottenstein-Programm, Medical Faculty, University of Freiburg, Freiburg, Germany
- ¹⁸ Department of Radiation Oncology, German Oncology Center, European University Cyprus, Nicosia, Cyprus
- ¹⁹ Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
- ²⁰ Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, USA